Novartis: Today's Positive Remibrutinib Data Key To Unlocking Growth Plans

Summary

Novartis announced positive data for remibrutinib, which the company views as key to unlocking its growth plans. The specific details of the trial phase, indication, and efficacy results are not provided in the headline.